CARM - Carisma Therapeutics Inc.
IEX Last Trade
0.4298
0.002 0.419%
Share volume: 1,500
Last Updated: Thu 26 Dec 2024 08:22:18 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
-0.11%
PREVIOUS CLOSE
CHG
CHG%
$0.43
0.00
0.42%
Fundamental analysis
27%
Profitability
29%
Dept financing
17%
Liquidity
75%
Performance
15%
Performance
5 Days
2.84%
1 Month
-53.06%
3 Months
-59.60%
6 Months
-67.30%
1 Year
-87.13%
2 Year
-96.09%
Key data
Stock price
$0.43
DAY RANGE
$0.41 - $0.43
52 WEEK RANGE
$0.41 - $3.07
52 WEEK CHANGE
-$87.00
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/07/2024
Company detail
CEO: Thomas R. Cannell
Region: US
Website: sesenbio.com
Employees: 20
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: sesenbio.com
Employees: 20
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Carisma Therapeutics Inc. a late-stage clinical company, focuses on designing, engineering, developing, and commercializing targeted fusion protein therapeutics (TFPTs) Its lead product candidates include Vicineum, which is in Phase III clinical trials for the treatment of bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer. The company was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.
Recent news